
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: Departments of 1 Medical Oncology and 2 Pathology, Yale University School of Medicine, New Haven, Connecticut and Departments of 3 Clinical Therapeutics and 4 Pathology, University of Athens School of Medicine, Athens, Greece
Requests for reprints: Amanda Psyrri, Yale Cancer Center, P.O. Box 208032, New Haven, CT 06520. Phone: 203-737-2476; Fax: 203-785-7531; E-mail: diamando.psyrri{at}yale.edu.
Purpose: p27 protein is regarded as a valuable prognostic biomarker in cancer with a potential use as a molecular target. However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of p27 in ovarian cancer using a novel method of compartmentalized in situ protein analysis.
Experimental Design: A tissue array composed of 150 advanced stage ovarian cancers uniformly treated, with surgical debulking followed by platinum-paclitaxel combination chemotherapy, was constructed. For evaluation of p27 protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis [automated quantitative analysis (AQUA)].
Results: The mean follow-up time of the patients was 34.3 months. Patients with low Fédération Internationale des Gynaecologistes et Obstetristes stage were more likely to have low nuclear p27 expression (P = 0.008). Low nuclear p27 expression was associated with improved 3-year overall survival (66% versus 20%, P = 0.0047) and disease-free survival (27% versus 12%, P = 0.022). In multivariable analysis, adjusting for well-characterized prognostic variables, low nuclear p27 expression level was the most significant prognostic factor for both disease-free and overall survival.
Conclusions: Our results indicate that quantitative assessment of nuclear p27 expression level by automated in situ quantitative analysis is a strong predictor for outcome in ovarian cancer.
This article has been cited by other articles:
![]() |
D. Mezzanzanica, M. Fabbi, M. Bagnoli, S. Staurengo, M. Losa, E. Balladore, P. Alberti, L. Lusa, A. Ditto, S. Ferrini, et al. Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients Clin. Cancer Res., March 15, 2008; 14(6): 1726 - 1733. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Bamias, Z Yu, P. Weinberger, S Markakis, D Kowalski, R. Camp, D. Rimm, M. Dimopoulos, and A Psyrri Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with {beta}-catenin levels and outcome in patients with epithelial ovarian cancer Ann. Onc., December 1, 2006; 17(12): 1797 - 1802. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Psyrri, Z. Yu, A. Bamias, P. M. Weinberger, S. Markakis, D. Kowalski, R. L. Camp, D. L. Rimm, and M. A. Dimopoulos Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1179 - 1183. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |